Lantern Pharma Inc.
SEC CIK 1763950 · LTRN · last insider filing 2026-05-14
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Keyser D Jeffrey | Director | filed 2020 - 2026 |
| Schalop Lee Troy | Director | filed 2025 - 2026 |
| Maccecchini Maria-Luisa | Director | filed 2022 - 2026 |
| Silberstein David S. | Director | filed 2020 - 2026 |
| Chandru Vijay | Director | filed 2020 - 2026 |
| Sharma Panna | Director · President and CEO | filed 2020 - 2025 |
| Kreis Leslie W. | Director | filed 2020 - 2025 |
| Prendergast Franklyn G | Director | filed 2020 - 2021 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Bhatia Kishor G. | Chief Scientific Officer | filed 2020 - 2025 |
| Margrave David R. | Chief Financial Officer | filed 2020 - 2025 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.